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S1PR1 drives a feedforward signalling loop to regulate BATF3
and the transcriptional programme of Hodgkin
lymphoma cells
K Vrzalikova1, M Ibrahim1, M Vockerodt1,2, T Perry1, S Margielewska1, L Lupino1, E Nagy1, E Soilleux3, D Liebelt1, R Hollows1, A Last1,
G Reynolds4, M Abdullah1,5, H Curley1, M Care6, D Krappmann7, R Tooze6, J Allegood8, S Spiegel8, W Wei1,9, CBJ Woodman1
and PG Murray1,10
The Hodgkin/Reed–Sternberg cells of classical Hodgkin lymphoma (HL) are characterised by the aberrant activation of multiple
signalling pathways. Here we show that a subset of HL displays altered expression of sphingosine-1-phosphate (S1P) receptors
(S1PR)s. S1P activates phosphatidylinositide 3-kinase (PI3-K) in these cells that is mediated by the increased expression of S1PR1
and the decreased expression of S1PR2. We also showed that genes regulated by the PI3-K signalling pathway in HL cell lines
significantly overlap with the transcriptional programme of primary HRS cells. Genes upregulated by the PI3-K pathway included
the basic leucine zipper transcription factor, ATF-like 3 (BATF3), which is normally associated with the development of dendritic
cells. Immunohistochemistry confirmed that BATF3 was expressed in HRS cells of most HL cases. In contrast, in normal lymphoid
tissues, BATF3 expression was confined to a small fraction of CD30-positive immunoblasts. Knockdown of BATF3 in HL cell lines
revealed that BATF3 contributed to the transcriptional programme of primary HRS cells, including the upregulation of S1PR1. Our
data suggest that disruption of this potentially oncogenic feedforward S1P signalling loop could provide novel therapeutic
opportunities for patients with HL.
Leukemia (2018) 32, 214–223; doi:10.1038/leu.2017.275
INTRODUCTION
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid meta-
bolite implicated in cancer growth, survival and invasion.1,2 S1P is
generated by the enzyme, sphingosine kinase 1 (SPHK1), which is
overexpressed in different cancer types, including some non-
Hodgkin lymphoma.3 Conversely, sphingosine-1-phosphate phos-
phatase (SGPP1), which degrades S1P, is downregulated during
tumour development and progression.4–6 Although the over-
production of S1P is a characteristic of many cancers, the
biological responses to S1P are governed by binding and
activation of five cell surface S1P receptors (S1PR1–5), each
coupling to a different repertoire of G proteins. In B cells, S1PR1
mediates mitogenic/prosurvival and chemotactic S1P functions by
coupling to Gi to activate Ras/ERK, phosphatidylinositide 3-kinase
(PI3-K)/Akt and Rac,7–9 whereas S1PR2 couples to G12/13 to inhibit
PI3-K/Akt activity leading to reduced cell growth, survival and
migration.10–14 S1PR1 has previously been reported to be over-
expressed in Hodgkin/Reed–Sternberg (HRS) cells and to promote
their migration in vitro.15 In contrast, S1PR2 may be a tumour
suppressor in B-cell lymphomas; previous studies show that S1PR2
is mutated in a subset of human diffuse large B-cell lymphoma
and that mice lacking S1PR2 expression develop diffuse large
B-cell lymphoma.16,17
Here we show that HRS cells are characterised by high
expression of SPHK1 and S1PR1, but do not express S1PR2. This
leads to enhanced PI3-K activation in response to S1P and to the
increased expression of the dendritic cell transcription factor (TF),
basic leucine zipper TF, ATF-like 3 (BATF3).18,19 In turn, BATF3
contributes to the transcriptional programme of Hodgkin lym-
phoma (HL), including the increased expression of S1PR1.
Interrupting this BATF3-regulated feedforward loop, for example,
by targeting S1PR1, could provide novel therapies for HL patients.
MATERIALS AND METHODS
Cells and tissues
Paediatric tonsils and tumour samples were obtained with informed
consent under local ethics committee approval (06/Q2702/50;
REC_RG_HBRC_12-071). Germinal center (GC) B cells were isolated and
characterised as described earlier.20–22 Isolation of blood-derived B cells
and preparation of lymphoblastoid cell lines were described before21–23
and are detailed in Supplementary Materials and Methods. KMH2, L428,
L1236 and L540 are Epstein–Barr virus (EBV)-negative HL cell lines and
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L591 is an EBV-positive HL cell line. DG75 is an EBV-negative Burkitt
lymphoma cell line. HEK293 is derived from human embryonic kidney. Cell
lines were cultured at 37 °C in 5% CO2 in either RPMI-1640 or DMEM
(HEK293) with 10% foetal calf serum and 1% penicillin–streptomycin (all
ThermoFisher Scientific, Waltham, MA, USA).
S1P measurements
For measurement of S1P levels in cell lines and B cells, lipids were
extracted and sphingolipids quantified by liquid chromatography-
electrospray ionisation-tandem mass spectrometry (4000 QTRAP; AB Sciex,
Framingham, MA, USA) as described previously.24
Treatment of cells
Preparation of S1P (Sigma-Aldrich, St Louis, MI, USA) is detailed in
Supplementary Materials and Methods. For S1P treatment, KMH2 cells
were washed two times, incubated in serum-free media for 1h, followed by
the addition of 1 μM S1P. S1P receptor functional antagonists, Ozanimod
(RPC1063; Selleckchem, Munich, Germany) or Siponimod (BAF312; Sell-
eckchem), were added to cells 1 h before stimulation with S1P for 15 min.
For measurement of viability, cells were stained using FITC Annexin V
Apoptosis Detection Kit I (BD Pharmingen, Franklin Lakes, NJ, USA) and
analysed by flow cytometry. For Akt inhibition, cells were cultivated in 10%
foetal calf serum media with 1μM Ipatasertib (GDC-0068; Selleckchem) or
vehicle (dimethyl sulfoxide) for 6 h. Cell-Titer Glo assay (Promega,
Fitchburg, WI, USA) showed no cell death at this time point.
For PI3-K inhibition, cells were cultivated in 10% foetal calf serum media
with 30 μM LY294002 or vehicle (dimethyl sulfoxide). We have previously
shown that LY294002 does not cause significant cell death at the time
points and concentration used.25
Gene expression in KMH2 cells following 16 h of LY294002/vehicle
treatment was analysed with Affymetrix HG-Focus Arrays (data available
from GSE89759, ThermoFisher Scientific). The data was background
subtracted and quantile normalised26,27 using the affy package of
Bioconductor. Differentially expressed genes were identified using
limma28 (Po0.05, absolute fold change 41.2). Probe sets with ‘Negative
Strand Matching Probes’ were removed from the significant gene list. Gene
ontology (GO) analysis was performed using DAVID 6.7 (http://david.abcc.
ncifcrf.gov) using GO-term BP-FAT; Po0.01, ⩾ 1.3-fold enrichment.
BATF3 knockdown
BATF3 knockdown was performed by nucleofection with Silencer Select
s195280 BATF3 siRNA or Silencer Select Negative Control No. 1 siRNA
(ThermoFisher Scientific). At 48h after BATF3 knockdown in L428 cells,
samples were hybridised to Affymetrix PrimeView Arrays (data available
from GSE89760, ThermoFisher Scientific) and data were analysed as
described above.
Reanalysis of publicly available data sets is described in Supplementary
Materials and Methods. χ2 test was used to identify significant enrichment
or depletion of either PI3-K or BATF3 target genes in these data sets using
a threshold for significance of Po0.05.
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Figure 1. Expression of SPHK1 in normal lymphoid tissues and HRS cells. (a) SPHK1 expression in GC B cells and primary HL. Black arrows show
HRS cells. (b) SPHK1 mRNA and (c) protein expression in HL cell lines. T1-4 are GC B cells isolated from four donors. Note: SPHK1 is
phosphorylated in all HL cell lines. (d) S1P levels in HL cell lines and B cells (mean of three different donors) measured by mass spectrometry.
GC, germinal center; MZ, mantle zone.
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Transfection of cells
GC B cells were nucleofected with pcDNA3.1-PRDM1 or empty vector,
cultivated and enriched as before.20,21 HL cell lines and DG75 cells were
transfected by Nucleofection (Lonza, Basel, Switzerland) and HEK293 cells
were transfected by Lipofectamine (ThermoFisher Scientific) using the
following vectors and corresponding controls: pcDNA3.1-S1PR2-HA (UMR
cDNA Resource Center University of Missouri-Rolla, Rolla, MO, USA), pSG5-
myc-p110α-CAAX (Julian Downward, Addgene, Cambridge, MA, USA),
Akt1/PKBα cDNA (activated) in pUSEamp containing a MYC tag (Merck
Millipore, Billerica, MA, USA), pcDNA3.1- S1PR1 (Dr Ian Paterson, University
of Malaya, Kuala Lumpur, Malaysia) and pCMV6-SPHK1 (Origene techno-
logies, Rockville, MD, USA).
Quantitative RT-PCR
RNA was extracted with RNeasy Mini/Micro Kit including genomic DNA
removal with RNase-Free DNase Set (Qiagen, Hilden, Germany). cDNA was
generated with qScript cDNA SuperMix (VWR International, Radnor, PA,
USA). Gene transcripts were quantified with commercial assays
(Supplementary Table S1A; ThermoFisher Scientific) as before.21 The
2−ΔCt method was used to quantify target expression relative to
glyceraldehyde 3-phosphate dehydrogenase housekeeping control (unless
specified otherwise).
Immunoblotting
Immunoblotting was performed with the primary antibodies detailed in
Supplementary Table S1B and following standard techniques described in
Supplementary Materials and Methods.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as before.29,30 Slides were
blocked in 5x casein followed by primary antibody in 0.05% PBS/Tween
(Supplementary Table S1C). Multiplex immunofluorescence (IF) was
performed using Opal 7-Plex Kit (NEL791001KT; Perkin-Elmer, Waltham,
MA, USA). For antibody stripping between each step, slides were
microwaved in pH6 citrate buffer, with controls omitting individual
antibody steps to ensure adequate stripping. Slides were scanned using
wide-range wavelength covering filters available in Vectra system 3.0.3
(Perkin-Elmer) (for dyes-cyanine 5, cyanine 3, DAPI, Texas Red, fluorescein).
Antibodies were optimised with autoexposure adjustment (100–150 ms).
Images were taken on Olympus BX-51WI microscope (Olympus, Tokyo,
Japan) with x10, x20 and x40 magnification. Multispectral images were
analysed using InForm Automated Image Analysis software version 2.2.1
(Perkin-Elmer) for phenotyping and quantification of coexpressed markers.
Analysis was performed with a x20 objective on a minimum of three fields
for cytospin preparations and five fields for tissue sections. For assessment
of protein expression following S1P treatment, the mean intensity and
standard deviation were calculated for each of three fields separately and
statistical significance was measured using Fisher's exact test. For image
analysis of tissue microarray we used the 1x1 function covering ~ 75% of
each core. Positivity in IHC was assessed with x40 objective using the
whole tissue microarray area, or 10 representative high power fields in the
case of whole sections. To directly compare our results with those
previously reported by Kluk et al.,15 S1PR1 was scored as positive if ⩾ 25%
of cells expressed S1PR1. The same cutoff was applied for all other
markers. Validation of the specificity of SPHK1, S1PR1, S1PR2 and BATF3
antibodies is shown in Supplementary Figure S1.
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Figure 2. Expression of S1PR1 and S1PR2 in normal lymphoid tissues and HRS cells. (a) Normal tonsil. Upper panels: S1PR1 expression in MZ B
cells, but not in GC B cells, confirmed by costaining for CD20. Lower panels: S1PR2 was expressed in normal GC B cells, confirmed by
costaining with CD20 (white arrow) and BCL6 (Supplementary Figure S4). (b) HRS cells expressed S1PR1 but not S1PR2 (white arrows)
confirmed by CD30 costaining. Endothelial cells and red blood cells were strongly positive for S1PR1 and S1PR2, respectively (black arrows).
Further examples of S1PR1 staining in HRS cells indicating the presence of both membrane and cytoplasmic staining are shown in
Supplementary Figure S5.
S1PR1, BATF3 and Hodgkin lymphoma
K Vrzalikova et al
216
Leukemia (2018) 214 – 223
RESULTS
Expression of SPHK1, SGPP1 and S1P receptors in HRS cells
We first studied the expression of SPHK1 and SGPP1, enzymes
important for regulating S1P levels.3–5 We showed that SPHK1 was
expressed in both normal GC B cells and in HRS cells in most cases
(49/58; Figure 1a and Supplementary Table S2). Owing to the lack of
an internal positive control we could not reliably quantify SPHK1
expression by IHC. Therefore, we reanalysed a microarray data set
that compared global gene expression in B-cell lymphomas with
that in normal B-cell subsets.31 This revealed significantly higher
SPHK1 mRNA in microdissected HRS cells compared with isolated
GC B cells (Supplementary Figure S2A). Reanalysis of a second
independent microarray data set32 revealed higher expression of
SPHK1 mRNA in both EBV-negative and EBV-positive HRS cells
compared with microdissected GCs (Supplementary Figure S2B).
Quantitative PCR showed that SPHK1 mRNA expression was also
higher in HL cell lines than in GC B cells (Figure 1b). We next used
immunoblotting to show that SPHK1 was constitutively activated in
HL cell lines (Figure 1c). Conversely, SGPP1 mRNA was decreased in
primary HRS cells and HL cell lines compared with normal GC B cells
(Supplementary Figure S3). Indeed, S1P levels measured by mass
spectrometry were higher in HL cells than in normal B cells
(Figure 1d). We next studied the expression of S1PR1 and S1PR2. We
showed that normal GC B cells expressed S1PR2, but not S1PR1
(Figure 2a and Supplementary Figure S4). In comparison, HRS cells
frequently expressed S1PR1 (36/61), but not S1PR2 (2/61), an
observation we confirmed by multiplex staining with CD30
(Figure 2b, Supplementary Figure S5 and Supplementary Table
S2). We conclude that in contrast to their normal counterparts, HRS
cells express high levels of SPHK1 and S1PR1 but lack expression of
S1PR2 and SGPP1.
S1P-induced PI3-K signalling in HRS cells is mediated by the
differential expression of S1P receptors
We next studied the effects of S1P on PI3-K signalling in HRS cells
using Akt phosphorylation as a readout. We chose the KMH2 cell
line for these experiments because it expresses S1PR1 and only
low levels of S1PR2 in the absence of the other S1P receptors
(Supplementary Figures S6A and B). We observed that the
addition of S1P increased Akt phosphorylation in KMH2 cells
(Figure 3a). To examine the effect of S1PR1 on Akt phosphoryla-
tion, we stimulated KMH2 cells with S1P after targeting S1PR1
(and S1PR5) with their functional antagonists Ozanimod and
Siponimod.33,34 The addition of either drug 1h before treatment
with S1P decreased Akt phosphorylation in a dose-dependent
manner (Figure 3b). Furthermore, Ozanimod significantly reduced
the viability of KMH2, L428 and L591 cells, while Siponimod
reduced the viability of KMH2 and L428 cells (Supplementary
Figure S7). L1236 was resistant to both drugs. To study the effect
of S1PR2, we transfected KMH2 cells with an S1PR2-HA expression
vector and used IF to detect phospho-Akt and the HA tag. Cells
ectopically expressing S1PR2 were significantly more likely to be
phospho-Akt negative than HA-negative cells in the same
transfected population, an effect we observed with (Po0.0001;
Supplementary Figure S8) and without (Po0.0001; not shown)
the addition of exogenous S1P. Taken together, our data suggest
that binding of S1P to S1PR1 can activate PI3-K signalling in
HRS cells.
Expression of the TF, BATF3, is regulated by PI3-K signalling in HRS
cells
To identify the transcriptional targets of PI3-K signalling pathway
in HL cells, we used the pan-PI3-K inhibitor LY294002. KMH2 cells
were treated with LY294002 for 16 h under conditions that do not
affect viability.25 The addition of LY294002 for 16 h was followed
by the upregulation of 694 genes and the downregulation of 330
genes (Supplementary Table S3). We validated a number of PI3-K
targets genes in KMH2, and also in L428, L591 and L1236 cells
(Supplementary Figure S9).
Reanalysis of GSE12453(ref. 31) identified 743 genes upregulated
and 622 genes downregulated in microdissected HRS cells
compared with normal centrocytes (Supplementary Table S4).
Genes upregulated in HRS cells (odds ratio (OR) = 2.15; Po0.0001),
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Figure 3. S1P activates Akt in HRS cells mediated by differential expression of S1P receptors. (a) Immunoblot of KMH2 cells following S1P
stimulation and (b) following 1 h pre-treatment with increasing concentrations of Ozanimod or Siponimod.
S1PR1, BATF3 and Hodgkin lymphoma
K Vrzalikova et al
217
Leukemia (2018) 214 – 223
but not those downregulated in HRS cells (OR = 1.00; P= 0.96),
were significantly enriched in genes downregulated following PI3-
K inhibition. Similarly, genes downregulated in HRS cells (OR=
2.95; Po0.0001), but not those upregulated in HRS cells
(OR= 1.28; P= 0.056), were significantly enriched in genes
upregulated following PI3-K inhibition (Supplementary
Figure S10 and Supplementary Table S5). These data indicate
that the activation of PI3-K signalling pathway contributes to the
transcriptional programme of HRS cells. We next wanted to
establish if this was also the case for both the EBV-positive and
EBV-negative forms of HL. To do this, we reanalysed data from the
second published microarray that had compared gene expression
in microdissected HRS cells with that in microdissected normal
GCs and which had reported EBV status for a subset of cases
GSE39133.32 The transcriptional targets of PI3-K signalling we had
identified in primary HRS cells were significantly enriched in those
genes differentially expressed in both EBV-positive and EBV-
negative HRS cells (Supplementary Figure S10 and Supplementary
Tables S6–S9).
A GO analysis revealed that genes regulated by the PI3-K
signalling pathway in primary HRS cells were enriched for those
with a function in ‘transcription initiation from RNA polymerase II
promoter’, suggesting that PI3-K signalling might contribute to
the aberrant expression of TFs observed in HRS cells (Figure 4a). To
identify relevant TF targets, we compared genes regulated by PI3-
K signalling in primary HRS cells with a comprehensive set of TFs
described by Vaquerizas et al.35 This revealed the upregulation of
12 TFs, and the downregulation of 47 TFs by PI3-K signalling in
HRS cells (Figure 4b). They included the dendritic cell TF,
BATF3,18,19 which was previously reported to be overexpressed
at the mRNA level in HRS cells36,37 and which was also the PI3-K
regulated gene most highly upregulated in the reanalysis of global
gene expression in primary HRS cells described above.31,32 We
confirmed that LY294002 downregulated BATF3 expression in HL
cell lines (Supplementary Figures S11A and B). Furthermore, the
pan-Akt inhibitor, Ipatasertib, also decreased BATF3 expression
(Supplementary Figure S11C). To confirm these were not off-target
effects, we transfected KMH2 cells with a MYC-tagged plasmid
Figure 4. PI3-K signalling upregulates BATF3 in HRS cells. (a) GO analysis of genes regulated by PI3-K signalling in primary HRS cells (GSE12453(ref. 31)
or GSE39133(ref. 32) data or both; total of 137 upregulated and 443 downregulated genes) revealed enrichment of several functions including
‘transcription initiation from RNA polymerase II promoter’. (b) Comparison of genes regulated by PI3-K signalling in primary HRS cells with a
comprehensive set of TFs revealed the upregulation of 12 TFs and the downregulation of 47 TFs by PI3-K signalling in HRS cells.
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containing a constitutively active p110 or Akt1 gene and
performed IF, titrating the MYC antibody to detect only exogenous
MYC. We found that a larger proportion of cells ectopically
expressing either p110 (Supplementary Figure S11D) or Akt1 (not
shown) were significantly more likely to be both phospho-Akt- and
BATF3-positive (Po0.0001) than were untransfected cells. Taken
together, our data show that activation of the PI3-K/Akt signalling
pathway leads to aberrant BATF3 expression in HL.
BATF3 overexpression contributes to the transcriptional
programme of HRS cells
We confirmed that BATF3 mRNA expression was higher in
microdissected HRS cells compared with normal B cells
(Supplementary Figure S12A) and in both EBV-positive and EBV-
negative HRS cells compared with microdissected GCs
(Supplementary Figure S12B). IHC of normal lymphoid tissues
revealed that BATF3 protein was not present in GC B cells and only
rarely in extrafollicular CD20-positive cells, which were also CD30-
positive (Figure 5a). In contrast, BATF3 protein was strongly
expressed in both EBV-positive (7/10) and EBV-negative (29/42)
HRS cells (Supplementary Table S10) confirmed by CD30 costain-
ing (Figure 5b), and in HL lines (Figures 5c and d). BATF3
expression was also increased after EBV infection of B cells
(Supplementary Figure S13).
A microarray analysis following BATF3 knockdown in L428 cells
revealed the upregulation of 960 genes and the downregulation
of 1066 genes (Supplementary Table S11A and B). Taking genes
only present on the Primeview platform (ThermoFisher Scientific)
and also on GSE12453,31 we found that genes downregulated by
BATF3 were significantly enriched in genes downregulated in
primary HRS cells (OR = 1.8; Po0.0001). A GO analysis of BATF3
target genes revealed the enrichment of a number of HL-related
GO terms, which included ‘lymphocyte differentiation’, ‘somatic
diversification of immune receptors’, ‘regulation of cell motion’,
‘positive regulation of transcription from RNA polymerase II
promoter’ and ‘B-cell-mediated immunity’ (Figure 6a). We
validated several BATF3 targets within different functional groups
including genes downregulated (JUN, FOS, ATF3, EGR1, EGR2,
PTPRC, CASP7, CASP14, RGS1, RGS16) and genes upregulated
(BACH2, STAT5B, CXCL16) by BATF3 (Supplementary Figure S14).
We noted that BATF3 decreased the expression of PRDM1, which
encodes BLIMP1 (Supplementary Figure S14), a TF downregulated
in HRS cells and which is essential for plasma cell
differentiation.21,38–41 Interrogation of our previous microarray
data set,21 which described the transcriptional changes that follow
the expression of BLIMP1 in primary GC B cells, also revealed a
reciprocal regulation of BATF3 by BLIMP1 (Supplementary
Figure S15A). We confirmed the downregulation of BATF3 by
BLIMP1 by quantitative PCR analysis of a further three donors
(Supplementary Figure S15B). These data show that the over-
expression of BATF3 contributes to the aberrant transcriptional
programme of HRS cells, including the downregulation of BLIMP1.
BATF3 upregulates S1PR1 expression
The knockdown of BATF3 significantly decreased S1PR1 mRNA
and protein levels in L428, L1236 and KMH2 cells (all Po0.0001;
Figure 7a and Supplementary Figure S16). In control and BATF3-
siRNA-treated cells (Po0.0001; Figure 7b) as well as in untreated
cells (Supplementary Table S12), BATF3 and S1PR1 levels were also
significantly correlated at the single-cell level. Next, we wanted to
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Figure 5. BATF3 is overexpressed in HRS cells. (a) IHC of normal tonsil. BATF3-positive cells were mainly located outside the GC, of which some
expressed CD20 and CD30 but not BCL6 (arrowed). (b) BATF3 expression in CD30-positive HRS cells (arrowed). (c) BATF3 mRNA and (d) protein
expression in HL cell lines. T1-T5 are GC B cells isolated from five donors. IF, interfollicular; MZ, mantle zone.
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show that this pathway was directly regulated by S1P. To do this,
we treated the HL cell lines with S1P or control (bovine serum
albumin) for 24 h and measured the levels of phospho-Akt, BATF3
and S1PR1 by IF. S1P significantly increased the levels of phospho-
Akt, BATF3 and S1PR1 in L428, KMH2 and L591 cells
(Supplementary Figure S17). This regulation could be observed
at the single-cell level because S1P-treated cells were significantly
more likely to coexpress phospho-Akt, BATF3 and S1PR1 (all
Po0.0001; not shown). S1P did not increase the expression of
phospho-Akt and BATF3 in L1236 cells, most likely owing to the
very high constitutively activated Akt in these cells and in keeping
with their resistance to S1PR1 inhibition described above. Finally,
we measured BATF3 and S1PR1 expression in primary HRS cells.
We found that BATF3-positive primary HL cases were significantly
more likely to be S1PR1-positive than BATF3-negative HL cases
(P= 0.0006; Supplementary Figure S18A and Supplementary Table
S10). Single-cell image analysis of six representative HL cases
showed that BATF3-positive HRS cells within each case were also
significantly more likely to be S1PR1-positive than were BATF3-
negative cells (Supplementary Figure S18B). Taken together, our
results suggest the existence of a feedforward S1P signalling loop
that drives constitutive BATF3 expression leading to aberrant
transcription in HRS cells.
DISCUSSION
Here we show that HRS cells express BATF3, a TF that is important
for the development of CD8α+ classical dendritic cells18 and
related non-lymphoid CD103+CD11b− dendritic cells.19 Reana-
lysis of existing global expression data sets and IHC showed that
BATF3 expression was significantly higher in primary HRS cells
compared with normal B cells. Our data also revealed that BATF3
is regulated by PI3-K/Akt signalling, a pathway we and others have
shown is constitutively activated in HRS cells.25,42,43
We also showed that the PI3-K/Akt signalling pathway is
regulated by S1P in HRS cells and that this is dependent on the
increased expression of S1PR1 together with the decreased
expression of S1PR2. The upregulation of S1PR1 in HRS cells has
been reported before,15 albeit in only 7/57 cases, a lower
proportion than we have reported here, despite the fact that we
used the same cutoff employed by Kluk et al.15 Our observation
that BATF3 induces the expression of S1PR1 identifies a
feedforward loop, which leads to constitutive S1P signalling,
activation of the PI3-K/Akt pathway and sustained BATF3
transcriptional activity (Figure 8). The major source of the S1P
necessary to sustain this loop is likely to be the HRS cells, as they
express SPHK1 in the absence of the S1P phosphatase, SGPP1. The
feedforward loop described here could be important for the
pathogenesis of HL as it has been shown that the knockdown of
BATF3 significantly reduces the survival of HL cell lines44 and that
BATF3 can induce B-cell lymphomas in a murine model (Weiser
et al, personal communication).
Our studies revealed that BATF3 downregulated expression of
PRDM1, which encodes BLIMP1, a TF required for plasma cell
differentiation and which is either mutated or transcriptionally
downregulated in B-cell lymphomas, including HL.21,38–41 BLIMP1
also decreased the expression of BATF3, indicating a reciprocal
regulation of BATF3 and BLIMP1. Furthermore, BATF3 increased
the expression of BACH2, which encodes a TF known to delay
BLIMP1 expression and plasma cell differentiation in mouse
Figure 6. BATF3 overexpression contributes to the transcriptional programme of HRS cells. GO analysis of BATF3 targets in L428 cells.
Immunoblotting shows knockdown of BATF3 in L428 cells.
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lymphocytes.45,46 These data suggest that the constitutive
expression of BATF3 could be important for the suppression of
terminal B-cell differentiation in HRS cell progenitors.
In keeping with the reported downregulation of AP-1 signalling
by BATF3,47 we observed that BATF3 decreased the transcription
of the key AP-1 components, JUN, FOS and ATF3. Furthermore, we
showed that BATF3 regulated many other transcriptional changes
characteristic of HRS cells. These included PTPRC (CD45), an
essential regulator of BCR signalling48,49 as well as STAT5B,
NOTCH1 and EGR1, encoding TFs known to be aberrantly
expressed in HRS cells.50–53
In a reanalysis of the BATF3 targets reported by Lollies et al.44
(using the same cutoff as in our array, but using short hairpin RNA
and different time point), we found that genes upregulated
(OR= 1.62; P= 0.003), but not those downregulated (OR= 0.96;
P= 0.89), by BATF3 in our array were significantly enriched in
those genes upregulated by BATF3 in Lollies et al.44 Similarly,
genes downregulated (OR= 2.7; Po0.00001), but not those
upregulated (OR = 0.82; P= 0.37), by BATF3 in our array were
significantly enriched in those genes downregulated by BATF3 in
Lollies et al.44 It is noteworthy that S1PR1 was among those genes
significantly upregulated by BATF3 in Lollies et al.44
Both EBV-positive and EBV-negative HRS cells expressed BATF3,
consistent with our observation that BATF3 expression was
increased by in vitro EBV infection. Because the EBV lytic cycle
has been shown to be induced upon terminal B-cell
differentiation54 leading to viral replication and cell death, the
increased BATF3 expression observed in EBV-infected tumour cells
could be important for suppression of the lytic cycle, in turn
preventing replication-induced cell death. In keeping with this,
several of the BATF3 targets we identified (for example, AP-1
components, EGR1, PRDM1) are known to induce the EBV lytic
cycle.21,55–59
Our data also suggest that the therapeutic blockade of S1P
signalling could inhibit the oncogenic effects of BATF3. The two
functional antagonists of S1PR1, Ozanimod and Siponimod, which
we showed can block the S1P-mediated activation of Akt, are
already in phase II and III clinical trials of patients with
inflammatory and autoimmune diseases. These and other S1PR1
BATF3 
S1PR1 
control BATF3 knockdown 
Figure 7. BATF3 regulates S1PR1 expression. Lower levels of S1PR1 protein were observed following BATF3 knockdown in L428 cells
(Po0.0001) shown here by IF (a) and confirmed by single-cell image analysis (b). BATF3 knockdown also significantly decreased S1PR1 protein
in L1236 and KMH2 cells (both Po0.0001; not shown).
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modulators should be investigated for their therapeutic
potential in HL.
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